The updated vaccine of the American pharmaceutical company Novavax against Covid-19 can be used for the ongoing vaccination campaign in France, according to a note from the Ministry of Health published Friday. This decision follows a European authorisation, at the end of October, to put on the market this Nuvaxovid vaccine, adapted to the XBB.1.5 strain of the Omicron variant, says the Directorate-General for Health (DGS) in a "DGS-Urgent" message addressed to all caregivers.
From next week, "pharmacies will be able to order again" vials of this vaccine, which is intended for adults and adolescents aged 12 and over, regardless of their vaccination history, but is not recommended for pregnant women pending additional data, the DGS said. It "offers an alternative for people who do not want or cannot receive a messenger RNA vaccine," according to the DGS, stressing that "booster vaccinations should, however, be carried out preferentially with mRNA vaccines."
In late November, Novavax reported that the World Health Organization (WHO) had granted its Nuvaxovid vaccine emergency use authorization, paving the way for "accelerated regulatory approvals in all 194 member states as well as UN procurement agencies, such as Unicef."
In parallel, the DGS announces that, the use of vaccines adapted to the majority circulating variants (Omicron XBB) being recommended, the VidPrevtyn Beta vaccine of the pharmaceutical group Sanofi, which has not been updated, will no longer be ordered by Public Health France. Until now, the DGS had proposed VidPrevtyn Beta as an alternative to mRNA vaccines while waiting for the availability of the updated Novavax.